Idenix Lands Blockbuster Deal With Novartis Around Antivirals

By all indications, it looks as if Idenix Pharmaceuticals Inc. has caught the eye of its new neighbor, Novartis Pharma AG, which is taking a controlling interest in Idenix and its viral drug programs through a deal that could be worth up to at least $862 million. (BioWorld Today)